PMID- 34007294
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210520
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - Mechanism of Huo-Xue-Qu-Yu Formula in Treating Nonalcoholic Hepatic Steatosis by 
      Regulating Lipid Metabolism and Oxidative Stress in Rats.
PG  - 6026319
LID - 10.1155/2021/6026319 [doi]
LID - 6026319
AB  - Huo-Xue-Qu-Yu formula (HXQYF) is a prescription consisting of Ginkgo biloba leaf 
      and Paeonia lactiflora Pall. for treating hyperlipidemia and NAFLD in China. 
      Here, we investigated the hepatic and renal function, oxidative stress and lipid 
      metabolism, and potential mechanisms of HXQYF on nonalcoholic fatty liver disease 
      (NAFLD) rat models. NAFLD rat models were induced with high-fat diet (HFD) and 
      10% fructose water for 18 weeks and orally administered with or without HXQYF 
      simultaneously. The results showed that HXQYF (22.5, 45, 90 mg/kg) significantly 
      improved blood lipid levels via reducing serum TC, TG, LDL-C, and APOB values and 
      elevating HDL-C and APOA1 levels in NAFLD rats. The higher levels of ALT, AST, 
      CR, and BUN in serum induced by HFD were reduced by HXQYF. HE staining showed 
      that HXQYF (90 mg/kg) reduced the accumulation of fat droplets and alleviated 
      inflammatory response in liver cells. Three doses of HXQYF exhibited notable 
      antioxidant effects by elevating SOD, GSH, and CAT activities and decreasing MDA 
      and OH-1 levels in the liver. Furthermore, abnormal lipid metabolism caused by 
      HFD was alleviated by HXQYF, which was associated with the upregulation of 
      PPAR-alpha, AdipoR2, and CPT1 mRNAs as well as the downregulation of CYP2E1 and 
      SREBP-1c mRNAs in liver tissue. In conclusion, our work verified that HXQYF could 
      reduce the degree of hepatic steatosis, suppress oxidative stress, and attenuate 
      lipid metabolism, thus preventing NAFLD.
CI  - Copyright (c) 2021 Bin Cheng et al.
FAU - Cheng, Bin
AU  - Cheng B
AD  - School of Chinese Materia Medica, Zhejiang Pharmaceutical College, Ningbo 310053, 
      China.
FAU - Zhou, Ai-Zhen
AU  - Zhou AZ
AD  - School of Chinese Materia Medica, Zhejiang Pharmaceutical College, Ningbo 310053, 
      China.
FAU - Ge, Wen
AU  - Ge W
AD  - School of Chinese Materia Medica, Zhejiang Pharmaceutical College, Ningbo 310053, 
      China.
AD  - Institute of Biopharmaceutical, Zhejiang Pharmaceutical College, Zhejiang, Ningbo 
      315100, China.
FAU - Yao, Xiao-Min
AU  - Yao XM
AD  - School of Pharmacy, Zhejiang Pharmaceutical College, Ningbo 310053, China.
FAU - Wang, Juan
AU  - Wang J
AUID- ORCID: 0000-0002-3202-6729
AD  - School of Chinese Materia Medica, Zhejiang Pharmaceutical College, Ningbo 310053, 
      China.
AD  - Institute of Biopharmaceutical, Zhejiang Pharmaceutical College, Zhejiang, Ningbo 
      315100, China.
LA  - eng
PT  - Journal Article
DEP - 20210429
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC8102110
COIS- The authors declare no conflicts of interest.
EDAT- 2021/05/20 06:00
MHDA- 2021/05/20 06:01
PMCR- 2021/04/29
CRDT- 2021/05/19 06:47
PHST- 2020/06/20 00:00 [received]
PHST- 2021/01/11 00:00 [revised]
PHST- 2021/04/15 00:00 [accepted]
PHST- 2021/05/19 06:47 [entrez]
PHST- 2021/05/20 06:00 [pubmed]
PHST- 2021/05/20 06:01 [medline]
PHST- 2021/04/29 00:00 [pmc-release]
AID - 10.1155/2021/6026319 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Apr 29;2021:6026319. doi: 
      10.1155/2021/6026319. eCollection 2021.